N
Nieves Diaz
Researcher at UCB
Publications - 4
Citations - 44
Nieves Diaz is an academic researcher from UCB. The author has contributed to research in topics: Tolerability & Volume of distribution. The author has an hindex of 4, co-authored 4 publications receiving 21 citations.
Papers
More filters
Journal ArticleDOI
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome
Maria Juarez,Nieves Diaz,Geoffrey I Johnston,Saba Nayar,Payne Andrew Charles,Eric Helmer,Dionne Cain,Paulette Williams,Valérie Devauchelle-Pensec,Benjamin A Fisher,Benjamin A Fisher,Roberto Giacomelli,Jacques-Eric Gottenberg,Giuliana Guggino,Marika Kvarnström,Xavier Mariette,Wan-Fai Ng,José Rosas,Juan Sanchez Burson,Giovanni Triolo,Francesca Barone,Simon J. Bowman +21 more
TL;DR: Despite enrolment challenges, seletalisib demonstrated a trend towards clinical improvement in patients with PSS and demonstrated efficacy in reducing size and organisation of salivary gland inflammatory foci and in target engagement, thus reducing PI3K-mTOR signalling compared with placebo.
Journal ArticleDOI
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Nieves Diaz,Maria Juarez,Caterina Cancrini,Caterina Cancrini,Maximilian Heeg,Pere Soler-Palacín,Payne Andrew Charles,Geoffrey I Johnston,Eric Helmer,Dionne Cain,Joanne Mann,Daisy Yuill,Francesca Conti,Francesca Conti,Silvia Di Cesare,Silvia Di Cesare,Stephan Ehl,Marina Garcia-Prat,Maria Elena Maccari,Andrea Martín-Nalda,Mónica Martínez-Gallo,Despina Moshous,Despina Moshous,Veronica Santilli,Michaela Semeraro,Michaela Semeraro,Alessandra Simonetti,Alessandra Simonetti,Felipe Suarez,Felipe Suarez,Marina Cavazzana,Sven Kracker,Sven Kracker +32 more
TL;DR: Patients with APDS receiving seletalisib had improvements in variable clinical and immunological features, and a favorable risk–benefit profile was maintained for ≤96 wk, which was generally maintained in the extension.
Journal ArticleDOI
A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14C]Seletalisib (UCB5857) in Healthy Subjects
Eric Helmer,Jean-Marie Nicolas,Jeff Long,Ad F. Roffel,Emma Jones,Hugues Chanteux,Nieves Diaz,Holly Garratt,Tjerk Bosje +8 more
TL;DR: This radiolabeled microtracer approach successfully informed on the absorption, distribution, metabolism, and excretion of seletalisib and further guided the mechanistic pharmacokinetic modeling.
Proceedings ArticleDOI
Ab0458 a phase ii randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary sjögren’s syndrome (pss)
Maria Juarez,Nieves Diaz,Geoffrey I Johnston,Saba Nayar,Payne Andrew Charles,Eric Helmer,Dionne Cain,Paulette Williams,Wan-Fai Ng,Benjamin A Fisher,Jacques-Eric Gottenberg,Giuliana Guggino,Xavier Mariette,Marika Kvarnström,Valérie Devauchelle-Pensec,José Rosas,Juan Sánchez-Bursón,Roberto Giacomelli,Francesca Barone,Simon J. Bowman +19 more
TL;DR: Although this Phase II PSS study was terminated early due to slow recruitment, seletalisib demonstrated a trend to clinical improvement in patients with PSS and acceptable safety and tolerability.